Terminated multicentre, national, observational, non-interventional, prospective study of paediatric patients with an acute infection of respiratory tract who were treated with erdosteine (Erdomed®).
start of the project: October 2014
end of the project: July 2018
Upper respiratory tract infections (URIs) are among the most common infections which bring patients to their GPs. Although URIs are mostly caused by viruses, antibiotics are often prescribed. Incorrect employment of antibiotics is one of the reasons why antibiotic resistance is on the rise. Excessive use of antibiotics still occurs, although a rational antibiotic policy is a key issue not only on the national level, but also across Europe (as supported by WHO activities).
Erdosteine, the active ingredient of Erdomed®, has not only mucolytic effects, but also has anti-adhesion properties against bacteria, and acts as an antioxidant and anti-inflammatory drug as well. It can therefore reduce bacterial colonisation and decrease the risk of bacterial superinfection. Since the majority of URIs in children are caused by viruses, it is rational to limit the empirical administration of antibiotics, and to start treatment with Erdomed® at early stages of URIs. Rationalisation and optimisation of treatment can be expected, as antibiotics would be only administered in indicated cases, and the therapeutic potential of Erdomed® would be fully utilised. Moreover, the GPs would cut their treatment costs in this way.
Primary objective of the project:
Secondary objective of the project:
Other important information: